logo.jpg
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
18 sept. 2024 05h00 HE | ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
ImCheck obtient 20,1
ImCheck obtient 20,18 millions d’euros de financement public dans le cadre du plan France 2030
29 août 2024 05h00 HE | ImCheck Therapeutics SAS
ImCheck reçoit un financement non-dilutif significatif afin d’accélérer l’avancement de deux programmes innovants, dans le traitement des cancer et des maladies infectieuses, en ligne avec l’ambition...
ImCheck Awarded EUR
ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
29 août 2024 05h00 HE | ImCheck Therapeutics SAS
FOR IMMEDIATE RELEASE -- ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France's 2030...
logo.jpg
ImCheck Appoints Stephan Braun as Chief Medical Officer
09 juil. 2024 05h00 HE | ImCheck Therapeutics SAS
ImCheck Appoints Stephan Braun as Chief Medical Officer         Marseille, France, July 09, 2024 – ImCheck Therapeutics announced today the appointment of Stephan Braun, M.D., Ph.D., as Chief...
logo.jpg
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
30 mai 2024 08h00 HE | ImCheck Therapeutics SAS
ImCheck to Present Promising ICT01 Datafrom the EVICTION Study at ASCO 2024 Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in combination...
logo.jpg
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
03 nov. 2023 14h00 HE | ImCheck Therapeutics SAS
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...
logo.jpg
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
30 oct. 2023 06h41 HE | ImCheck Therapeutics SAS
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting          Marseille, France, October 30, 2023 – ImCheck...
logo.jpg
Correction: ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
18 oct. 2023 15h50 HE | ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
logo.jpg
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
15 oct. 2023 18h05 HE | ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
logo.jpg
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
18 avr. 2023 09h00 HE | ImCheck Therapeutics SAS
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023 ICT01 in combination with low dose IL-2 safely...